The Promise of a Prophylactic Epstein-Barr Virus Vaccine

Overview

Journal Pediatr Res

Specialties Biology
Pediatrics

Date 2019 Oct 24

PMID 31641280

Citations 21

Authors

Henry H Balfour Jr

David O Schmeling

Jennifer M Grimm-Geris

Affiliations

Soon will be listed here.

Abstract

The worldwide burden of disease due to Epstein-Barr virus (EBV) infection is enormous. Diseases include endemic Burkitt lymphoma, infectious mononucleosis, cancers after transplantation, Hodgkin lymphoma, and nasopharyngeal carcinoma. A prophylactic EBV vaccine has the potential to significantly reduce the incidence and/or the severity of all these diseases. Infectious mononucleosis can be nasty and prolonged with a median duration of 17 days. Patients, especially children, undergoing bone marrow or solid organ transplantation may develop post-transplant lymphoproliferative disorder (PTLD). Preventing or modifying primary EBV infection could reduce the incidence PTLD, and also certain lymphomas and nasopharyngeal carcinoma. EBV is a major environmental risk factor for multiple sclerosis (MS). Contracting EBV is essential to getting MS, and having a childhood case of infectious mononucleosis increases that risk. Vaccinating against EBV could be vaccinating against MS.

Citing Articles

Cracking the Codes behind Cancer Cells' Immune Evasion.

Mundhara N, Sadhukhan P Int J Mol Sci. 2024; 25(16).

PMID: 39201585 PMC: 11354234. DOI: 10.3390/ijms25168899.

Applications of cell therapy in the treatment of virus-associated cancers.

Toner K, McCann C, Bollard C Nat Rev Clin Oncol. 2024; 21(10):709-724.

PMID: 39160243 DOI: 10.1038/s41571-024-00930-x.

Pediatric Kidney Transplantation: Cancer and Cancer Risk.

Order K, Rodig N Semin Nephrol. 2024; 44(1):151501.

PMID: 38580568 PMC: 11734768. DOI: 10.1016/j.semnephrol.2024.151501.

Role of long non-coding RNA in chemoradiotherapy resistance of nasopharyngeal carcinoma.

Yang Y, Yuan Q, Tang W, Ma Y, Duan J, Yang G Front Oncol. 2024; 14:1346413.

PMID: 38487724 PMC: 10937456. DOI: 10.3389/fonc.2024.1346413.

Insights into the interplay between Epstein-Barr virus (EBV) and multiple sclerosis (MS): A state-of-the-art review and implications for vaccine development.

Mohammadzamani M, Kazemzadeh K, Chand S, Thapa S, Ebrahimi N, Yazdan Panah M Health Sci Rep. 2024; 7(2):e1898.

PMID: 38361801 PMC: 10867693. DOI: 10.1002/hsr2.1898.

References

Epstein M, ACHONG B, BARR Y . VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. Lancet. 1964; 1(7335):702-3. DOI: 10.1016/s0140-6736(64)91524-7. View

Epstein M, ACHONG B . The EB virus. Annu Rev Microbiol. 1973; 27:413-36. DOI: 10.1146/annurev.mi.27.100173.002213. View

BURKITT D . A sarcoma involving the jaws in African children. Br J Surg. 1958; 46(197):218-23. DOI: 10.1002/bjs.18004619704. View

Rainey J, Omenah D, Sumba P, Moormann A, Rochford R, Wilson M . Spatial clustering of endemic Burkitt's lymphoma in high-risk regions of Kenya. Int J Cancer. 2006; 120(1):121-7. DOI: 10.1002/ijc.22179. View

Petersson F . Nasopharyngeal carcinoma: a review. Semin Diagn Pathol. 2015; 32(1):54-73. DOI: 10.1053/j.semdp.2015.02.021. View

Cao S, Simons M, Qian C . The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer. 2011; 30(2):114-9. PMC: 4013340. DOI: 10.5732/cjc.010.10377. View

Old L, Boyse E, Oettgen H, Harven E, Geering G, Williamson B . Precipitating antibody in human serum to an antigen present in cultured burkitt's lymphoma cells. Proc Natl Acad Sci U S A. 1966; 56(6):1699-704. PMC: 220158. DOI: 10.1073/pnas.56.6.1699. View

zur Hausen H, SCHULTE-HOLTHAUSEN H, Klein G, Henle W, Henle G, Clifford P . EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature. 1970; 228(5276):1056-8. DOI: 10.1038/2281056a0. View

Wara W, Wara D, Phillips T, Ammann A . Elevated IGA in carcinoma of the nasopharynx. Cancer. 1975; 35(5):1313-5. DOI: 10.1002/1097-0142(197505)35:5<1313::aid-cncr2820350510>3.0.co;2-b. View

10.

Henle G, Henle W . Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer. 1976; 17(1):1-7. DOI: 10.1002/ijc.2910170102. View

11.

Lo Y, Chan L, Lo K, Leung S, Zhang J, Chan A . Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 1999; 59(6):1188-91. View

12.

Hui E, Taylor G, Jia H, Ma B, Chan S, Ho R . Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer Res. 2013; 73(6):1676-88. PMC: 6485495. DOI: 10.1158/0008-5472.CAN-12-2448. View

13.

Briaud B, Lutz B, MIALHE C . [Adrenocortical response to an acoustic neurotropic stress: influence of the frequency and repetition of the stimulus]. C R Seances Soc Biol Fil. 1971; 165(6):1435-40. View

14.

Ascherio A, Munch M . Epstein-Barr virus and multiple sclerosis. Epidemiology. 2000; 11(2):220-4. DOI: 10.1097/00001648-200003000-00023. View

15.

. Issues in pediatric critical care. Crit Care Clin. 1988; 4(4):645-885. View

16.

Mauvais-Jarvis P . [Benign mastopathies and breast carcinogenesis: a reappraisal]. Presse Med. 1985; 14(30):1585-6. View

17.

Compton M, Seale J, Shaw J . Effects of aerosol antigen challenge in vivo on responsiveness of guinea pig tracheal and parenchymal strips in vitro to contractile agonists. Int Arch Allergy Appl Immunol. 1987; 84(1):40-4. DOI: 10.1159/000234396. View

18.

Unger H . [Destructive processes of the vertebral column]. Z Arztl Fortbild (Jena). 1966; 60(13):796-800. View

19.

. [The new dental porcelain material Vitadur]. Zahntechnik (Zur). 1967; 25(3):360-1. View

20.

Vetulani J . [Pharmacology of isoxazole and pyrazole derivatives]. Postepy Hig Med Dosw. 1968; 22(2):315-30. View